AI Summary

SIA Latima is a Latvian biotechnology company founded in 1992, specializing in the development and production of oncolytic viruses, notably the ECHO-7 virus Rigvir. The company focuses on research, manufacturing, and licensing within the healthcare sector, targeting medical professionals, researchers, and patients interested in innovative cancer treatments. The website content is primarily in Latvian with an option for English, providing detailed business descriptions and historical contract information, but lacks privacy and security policy disclosures. Technically, the website employs Bootstrap 3 and jQuery 1.11.1, indicating an older technology stack. The site is moderately optimized for performance and mobile use but lacks advanced accessibility and SEO features. No CMS or hosting provider information is discernible. Security posture is limited, with no detected security headers or HTTPS verification in the provided data, and no forms or analytics scripts are present. Security evaluation reveals gaps in privacy compliance and security best practices, including missing privacy and cookie policies, absence of security headers, and no incident response information. The WHOIS data could not be retrieved due to query limits, limiting domain registration trust analysis. Overall, the site appears legitimate and professional but would benefit from enhanced security and compliance measures. The overall risk is moderate with recommendations to implement HTTPS, add security headers, publish privacy and cookie policies, and improve contact transparency to enhance trust and compliance.